134 related articles for article (PubMed ID: 32151585)
1. Impact of the Conditioning Regimen Dose Intensity Before Autologous Stem Cell Transplantation on the Pulmonary Function Test Abnormalities in Patients With Lymphoma and Multiple Myeloma: Single Center Experience.
Bou Akl I; Matar M; Khalil PB; Massoud R; Ghaoui N; Karout L; Zahreddine A; Bazarbachi A; El-Cheikh J
Clin Lymphoma Myeloma Leuk; 2020 Jun; 20(6):371-376.e1. PubMed ID: 32151585
[TBL] [Abstract][Full Text] [Related]
2. Assessment of pulmonary and cardiac function after high dose chemotherapy with BEAM and peripheral blood progenitor cell transplantation.
Salloum E; Jillella AP; Nadkarni R; Seropian S; Hu GL; D'Andrea E; Zelterman D; Cooper DL
Cancer; 1998 Apr; 82(8):1506-12. PubMed ID: 9554528
[TBL] [Abstract][Full Text] [Related]
3. Carmustine, etoposide, cytarabine, and melphalan (BEAM)-campath allogeneic stem cell transplantation for aggressive non-hodgkin lymphoma: an analysis of outcomes from the British Society of Blood and Marrow Transplantation.
Truelove E; Fox C; Robinson S; Pearce R; Perry J; Kirkland K; McQuaker G; Pagliuca A; Johnson P; Russell N; Cook G;
Biol Blood Marrow Transplant; 2015 Mar; 21(3):483-8. PubMed ID: 25490180
[TBL] [Abstract][Full Text] [Related]
4. A phase II study of V-BEAM as conditioning regimen before second auto-SCT for multiple myeloma.
Wang TF; Fiala MA; Cashen AF; Uy GL; Abboud CN; Fletcher T; Wu N; Westervelt P; DiPersio JF; Stockerl-Goldstein KE; Vij R
Bone Marrow Transplant; 2014 Nov; 49(11):1366-70. PubMed ID: 25068418
[TBL] [Abstract][Full Text] [Related]
5. Carmustine, etoposide, cytarabine and melphalan as a preparative regimen for allogeneic transplantation for high-risk malignant lymphoma.
Przepiorka D; van Besien K; Khouri I; Hagemeister F; Samuels B; Folloder J; Ueno NT; Molldrem J; Mehra R; Körbling M; Giralt S; Gajewski J; Donato M; Cleary K; Claxton D; Braunschweig I; Andersson B; Anderlini P; Champlin R
Ann Oncol; 1999 May; 10(5):527-32. PubMed ID: 10416001
[TBL] [Abstract][Full Text] [Related]
6. High-dose CEB vs BEAM with autologous stem cell transplant in lymphoma.
Wang EH; Chen YA; Corringham S; Bashey A; Holman P; Ball ED; Carrier E
Bone Marrow Transplant; 2004 Oct; 34(7):581-7. PubMed ID: 15273714
[TBL] [Abstract][Full Text] [Related]
7. Thiotepa-based high-dose therapy for autologous stem cell transplantation in lymphoma: a retrospective study from the EBMT.
Sellner L; Boumendil A; Finel H; Choquet S; de Rosa G; Falzetti F; Scime R; Kobbe G; Ferrara F; Delmer A; Sayer H; Amorim S; Bouabdallah R; Finke J; Salles G; Yakoub-Agha I; Faber E; Nicolas-Virelizier E; Facchini L; Vallisa D; Zuffa E; Sureda A; Dreger P;
Bone Marrow Transplant; 2016 Feb; 51(2):212-218. PubMed ID: 26569093
[TBL] [Abstract][Full Text] [Related]
8. Autologous stem cell transplantation for follicular lymphoma: no benefit for early transplant?
Seyfarth B; Kuse R; Sonnen R; Glass B; Schmitz N; Dreger P
Ann Hematol; 2001 Jul; 80(7):398-405. PubMed ID: 11529465
[TBL] [Abstract][Full Text] [Related]
9. Phase II Study of Propylene Glycol-Free Melphalan Combined with Carmustine, Etoposide, and Cytarabine for Myeloablative Conditioning in Lymphoma Patients Undergoing Autologous Stem Cell Transplantation.
Cashen AF; Fletcher T; Ceriotti C; Gao F; Ghobadi A; Vij R; Stockerl-Goldstein K; DiPersio J; Abboud C
Biol Blood Marrow Transplant; 2016 Dec; 22(12):2155-2158. PubMed ID: 27575541
[TBL] [Abstract][Full Text] [Related]
10. Allogeneic stem cell transplantation for relapsed or refractory lymphoma after conditioning with BEAM/fludarabine/TBI.
O'Meara A; Halter J; Heim D; Gerull S; Bucher C; Passweg J; Buser A; Stern M
Biol Blood Marrow Transplant; 2013 Jan; 19(1):82-6. PubMed ID: 22897965
[TBL] [Abstract][Full Text] [Related]
11. Utility of routine pulmonary function test after autologous hematopoietic cell transplantation in lymphoma.
Dahi PB; Kenny S; Flynn J; Devlin SM; Ruiz JD; Chinapen SA; Lahoud OB; Matasar MJ; Moskowitz CH; Perales MA; Shah G; Sauter CS; Giralt SA; Geyer AI; Jakubowski AA
Leuk Lymphoma; 2023 Dec; 64(14):2279-2285. PubMed ID: 37690007
[TBL] [Abstract][Full Text] [Related]
12. Autologous noncryopreserved hematopoietic stem cell transplant with CEAM as a modified conditioning regimen in patients with Hodgkin lymphoma: a single-center experience with a new protocol.
Ramzi M; Mohamadian M; Vojdani R; Dehghani M; Nourani H; Zakerinia M; Haghighinejad H
Exp Clin Transplant; 2012 Apr; 10(2):163-7. PubMed ID: 22432762
[TBL] [Abstract][Full Text] [Related]
13. Autologous transplantation for transformed non-Hodgkin lymphoma using an yttrium-90 ibritumomab tiuxetan conditioning regimen.
Mei M; Wondergem MJ; Palmer JM; Shimoni A; Hasenkamp J; Tsai NC; Simpson J; Nademanee A; Raubitschek A; Forman SJ; Krishnan AY
Biol Blood Marrow Transplant; 2014 Dec; 20(12):2072-5. PubMed ID: 25079874
[TBL] [Abstract][Full Text] [Related]
14. Total body irradiation compared with BEAM: Long-term outcomes of peripheral blood autologous stem cell transplantation for non-Hodgkin's lymphoma.
Liu HW; Seftel MD; Rubinger M; Szwajcer D; Demers A; Nugent Z; Schroeder G; Butler JB; Cooke A
Int J Radiat Oncol Biol Phys; 2010 Oct; 78(2):513-20. PubMed ID: 20137862
[TBL] [Abstract][Full Text] [Related]
15. Zevalin and BEAM (Z-BEAM) versus rituximab and BEAM (R-BEAM) conditioning chemotherapy prior to autologous stem cell transplantation in patients with mantle cell lymphoma.
Berger MD; Branger G; Klaeser B; Taleghani BM; Novak U; Banz Y; Mueller BU; Pabst T
Hematol Oncol; 2016 Sep; 34(3):133-9. PubMed ID: 25689832
[TBL] [Abstract][Full Text] [Related]
16. Self-reported experience of mucositis in cancer patients who underwent conditioning regimen and stem cell transplantation.
Ozturk M; Komurcu S; Kilic S; Ozet A; Arpaci F; Ozturk B; Kuzhan O; Ataergin S
Support Care Cancer; 2009 Oct; 17(10):1295-9. PubMed ID: 19198890
[TBL] [Abstract][Full Text] [Related]
17. Dexamethasone, carmustine, etoposide, cytarabine, and melphalan (dexa-BEAM) followed by high-dose chemotherapy and stem cell rescue--a highly effective regimen for patients with refractory or relapsed indolent lymphoma.
Josting A; Reiser M; Wickramanayake PD; Rueffer U; Draube A; Söhngen D; Tesch H; Wolf J; Diehl V; Engert A
Leuk Lymphoma; 2000 Mar; 37(1-2):115-23. PubMed ID: 10721775
[TBL] [Abstract][Full Text] [Related]
18. Positron emission tomography with [18F]2-fluoro-D-2-deoxyglucose (FDG-PET) predicts relapse of malignant lymphoma after high-dose therapy with stem cell transplantation.
Becherer A; Mitterbauer M; Jaeger U; Kalhs P; Greinix HT; Karanikas G; Pötzi C; Raderer M; Dudczak R; Kletter K
Leukemia; 2002 Feb; 16(2):260-7. PubMed ID: 11840293
[TBL] [Abstract][Full Text] [Related]
19. Conditioning regimen with BCNU, etoposide, cytarabine and melphalan plus amifostine for outpatient autologous stem cell transplant: feasibility and outcome in 97 patients with lymphoma.
Scortechini I; Montanari M; Mancini G; Inglese E; Calandrelli M; Chiarucci M; Offidani M; Capelli D; Gini G; Poloni A; Mancini S; Raggetti G; Leoni P; Olivieri A
Leuk Lymphoma; 2014 Jul; 55(7):1657-60. PubMed ID: 24024474
[No Abstract] [Full Text] [Related]
20. Autologous Hematopoietic Stem Cell Transplantation-10 Years of Data From a Developing Country.
Ali N; Adil SN; Shaikh MU
Stem Cells Transl Med; 2015 Aug; 4(8):873-7. PubMed ID: 26032748
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
